AU Patent

AU2023202085A1 — Polymorphic forms of RAD1901-2HCL

Assigned to Radius Pharmaceuticals Inc · Expires 2023-05-04 · 3y expired

What this patent protects

POLYMORPHIC FORMS OF RAD1901-2HCL ABSTRACT Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic form of RAD190-2HCl for cancer treatment are also disclosed.

USPTO Abstract

POLYMORPHIC FORMS OF RAD1901-2HCL ABSTRACT Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic form of RAD190-2HCl for cancer treatment are also disclosed.

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: AU2023202085A1
Jurisdiction: AU
Classification: —
Expires: 2023-05-04
Drug substance claim: No
Drug product claim: No
Assignee: Radius Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.